Cabaletta Bio Stockholders Approve Key Proposals

The latest update is out from Cabaletta Bio ( (CABA) ).

On June 9, 2025, Cabaletta Bio held its Annual Meeting of Stockholders where several key proposals were voted on. Stockholders elected two directors, ratified the appointment of Ernst & Young LLP as the independent auditor, approved an amendment to increase authorized shares, and decided on the frequency of advisory votes on executive compensation. These decisions are pivotal for the company’s governance and operational flexibility, potentially impacting its strategic direction and shareholder engagement.

The most recent analyst rating on (CABA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.

Spark’s Take on CABA Stock

According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.

Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.

To see Spark’s full report on CABA stock, click here.

More about Cabaletta Bio

Cabaletta Bio, Inc. operates in the biotechnology industry, focusing on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

Average Trading Volume: 1,422,571

Technical Sentiment Signal: Sell

Current Market Cap: $125.8M

See more data about CABA stock on TipRanks’ Stock Analysis page.